Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Dateline City:
KENILWORTH, N.J.
Phase 1 Data Presented Today at IAS 2019
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for extended administration of islatravir, the company’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), in healthy volunteers.
Language:
English
Contact:
Media Contacts:
Pamela Eisele
(267) 305-3558
Sarra S. Herzog
(201) 669-6570
Investor Contacts:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
